Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users

Psychopharmacology

Volumn 220, Issue 4, 2012, Pages 751-762

  Brunt, Tibor M ^a   Koeter, Maarten W ^b   Niesink, Raymond J M ^a   Van Den Brink, Wim ^b  

^a NETHERLANDS INSTITUTE OF MENTAL HEALTH AND ADDICTION   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

3,4 Methylenedioxymethamphetamine (MDMA); Adverse; Desirable; Dose; Ecstasy; Subjective effects

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 1 BENZYLPIPERAZINE DERIVATIVE; 3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 FLUOROAMPHETAMINE; 4 METHOXYMETHAMPHETAMINE; 4' METHYLMETHCATHINONE; AMPHETAMINE; AMPHETAMINE DERIVATIVE; CAFFEINE; METOCLOPRAMIDE; N ETHYL 3,4 METHYLENEDIOXYAMPHETAMINE; UNCLASSIFIED DRUG; STREET DRUG;

ABDOMINAL CRAMP; AGITATION; ALLERGIC REACTION; AROUSAL; ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; DIZZINESS; DRUG ABUSE; EUPHORIA; EXPERIENCE; HALLUCINATION; HEADACHE; HEART PALPITATION; HUMAN; HYPERTHERMIA; LEISURE; MAJOR CLINICAL STUDY; NAUSEA; NETHERLANDS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEIZURE; SELF REPORT; TABLET; CHEMISTRY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG USE; PSYCHOLOGICAL ASPECT;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG USERS; HUMANS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NETHERLANDS; SELF REPORT; STREET DRUGS; TABLETS;

EID: 84871900847     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2529-4     Document Type: Article

References (76)

1. Aerts LA, Mallaret M, Rigter H. (2000) N-Methyl-1-(1,3-benzodioxol-5-yl)- 2-butanamine (MBDB): its properties and possible risks. Addict Biol 5:269-282
2. Antia U, Lee HS, Kydd R.R., Tingle MD, Russell B.R. (2009) Pharmacokinetics of 'party pill' drug N-benzylpiperazine (BZP) in healthy human participants. Forensic Sci Int 186:63-67
3. Baylen CA, Rosenberg H. (2006) A review of the acute subjective effects of MDMA/ecstasy. Addiction 101:933-947
4. Becker J, Neis P, Röhrich J, Zörntlein S (2003) A fatal paramethox-ymethamphetamine intoxication. Leg Med (Tokyo) 5:S138-S141
5. Bossong MG, Van Dijk JP, Niesink R.J. (2005) Methylone and mCPP, two new drugs of abuse? Addict Biol 10:321-323
6. Bossong M, Brunt TM, Van Dijk JP, Rigter S, Hoek J, Goldschmidt H., Niesink R.J. (2010) mCPP: an undesired addition to the ecstasy market. J Psychopharmacol 24:1395-1401
7. Boyer EW, Quang L, Woolf A., Shannon M, Magnani B. (2001) Dextromethorphan and ecstasy pills. JAMA 285:409-410
8. Brunt TM, Poortman A, Niesink R.J., van den Brink W (2010) Instability of the ecstasy market and a new kid on the block: mephedrone. J Psychopharmacol. doi:10.1177/0269881110378370
9. Butler RA, Sheridan J.L. (2007) Highs and lows: patterns of use, positive and negative effects of benzylpiperazine-containing party pills (BZP-party pills) amongst young people in New Zealand. Harm Reduct J 4:18
10. Bytzer P, Hallas J. (2000) Drug-induced symptoms of functional dyspepsia and nausea. A symmetry analysis of one million prescriptions. Aliment Pharmacol Ther 14:1479-1484
11. Caldicott DG, Edwards NA, Kruys A, Kirkbride K.P., Sims DN, Byard RW, Prior M, Irvine R.J. (2003) Dancing with "death": p-methoxyamphetamine overdose and its acute management. J Toxicol Clin Toxicol 41:143-154
12. Callaghan PD, Irvine RJ, Daws L.C. (2005) Differences in the in vivo dynamics of neurotransmitter release and serotonin uptake after acute para-methoxyamphetamine and 3,4-methylenedioxyme-thamphetamine revealed by chronoamperometry. Neurochem Int 47:350-361
13. Camilleri AM, Caldicott D. (2005) Underground pill testing, down under. Forensic Sci Int 151:53-58
14. Carhart-Harris R.L., King LA, Nutt D.J. (2011) A web-based survey on mephedrone. Drug Alcohol Depend. doi:10.1016/ j.drugalcdep.2011.02.011
15. Cohen BM, Butler R. (2010) BZP-party pills: a review of research on benzylpiperazine as a recreational drug. Int J Drug Policy 22:95-101
16. Cole JC, Bailey M, Sumnall H.R., Wagstaff GF, King L.A. (2002) The content of ecstasy tablets: implications for the study of their longterm effects. Addiction 97:1531-1536
17. Cunningham RS (1997) 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy. Oncol Nurs Forum 24:33-40
18. de Boer D., Bosman IJ, Hidvégi E, Manzoni C., Benkö AA, dos Reys LJ, Maes RA (2001) Piperazine-like compounds: a new group of designer drugs-of-abuse on the European market. Forensic Sci Int 121:47-56
19. Dumont GJ, Verkes R.J. (2006) A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers. J Psy-chopharmacol 20:176-187
20. EMCDDA (2003-2011) European information system and database on new drugs, EWS final reports 2003-2011, http://ednd.emcdda.europa.eu/
21. EMCDDA (2010) European Monitoring Centre for Drugs and Drug Addiction, Annual Report 2010, http://www.emcdda.europa.eu/attachements.cfm/att-120104-EN- EMCDDA-AR2010-EN.pdf
22. Erowid (2006) Erowid 4-Fluoroamphetamine (para-Fluoroamphetamine) Vault, http://www.erowid.org/chemicals/4-fluoroamphetamine/
23. Erowid (2010) Erowid Experience Vaults: 4-Methylmethcathinone Reports, http://www.erowid.org/experiences/subs/exp-4Methylmethcathinone.shtml
24. Europol-EMCDDA (2010) Annual Report on the implementation of Council Decision 2005/387/JHA, http://www.emcdda.europa.eu/attachements.cfm/att-132857- EN-EMCDDA-Europol%20Annual%20Report%202010A.pdf
25. Feuchtl A, Bagli M, Stephan R., Frahnert C, Kölsch H, Kühn KU, Rao ML (2004) Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile. Pharmacopsychia-try 37:180-188
26. Gijsman HJ, Cohen AF, van Gerven JM (2004) The application of the principles of clinical drug development to pharmacological challenge tests of the serotonergic system. J Psychopharmacol 18:7-13
27. Giraudon I, Bello PY (2007) Monitoring ecstasy content in France: results from the National Surveillance System 1999-2004. Subst Use Misuse 42:1567-1578
28. Glennon RA, Ismaiel AE, McCarthy B.G., Peroutka S.J. (1989) Binding of arylpiperazines to 5-HT3 serotonin receptors: results of a structure-affinity study. Eur J Pharmacol 168:387-392
29. Gouzoulis-Mayfrank E., Thelen B, Habermeyer E., Kunert HJ, Kovar KA, Lindenblatt H, Hermle L., Spitzer M, Sass H (1999) Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and D-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacol-ogy Berl 142:41-50
30. Hegadoren KM, Baker GB, Bourin M. (1999) 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. Neurosci Biobehav Rev 23:539-553
31. Hermle L, Spitzer M, Borchardt D., Kovar KA, Gouzoulis E. (1993) Psychological effects of MDE in normal subjects. Are entac-togens a new class of psychoactive agents? Neuropsychophar-macology 8:171-176
32. Higgins GA, Kilpatrick G.J. (1999) 5-HT(3) receptor antagonists. Expert Opin Investig Drugs 8:2183-2188
33. Hiyama T, Yoshihara M, Tanaka S., Haruma K, Chayama K. (2009) Effectiveness of prokinetic agents against diseases external to the gastrointestinal tract. J Gastroenterol Hepatol 24:537-546
34. Hosmer DW, Lemeshow S. (2000) Applied logistic regression, 2nd edn. Wiley, University of Massachusetts, Massachusetts
35. Huxster JK, Pirona A, Morgan M.J. (2006) The sub-acute effects of recreational ecstasy (MDMA) use: a controlled study in humans. J Psychopharmacol 20:281-290
36. Jan RK, Lin JC, Lee H, Sheridan J.L., Kydd RR, Kirk IJ, Russell B.R. (2010) Determining the subjective effects of TFMPP in human males. Psychopharmacology Berl 211:347-353
37. Johnstone AC, Lea RA, Brennan K.A., Schenk S., Kennedy MA, Fitzmaurice P.S. (2007) Benzylpiperazine: a drug of abuse? J Psychopharmacol 21:888-894
38. Johansen SS, Hansen AC, Müller IB, Lundemose J.B., Franzmann M.B. (2003) Three fatal cases of PMA and PMMA poisoning in Denmark. J Anal Toxicol 27:253-256
39. Kalasinsky KS, Hugel J, Kish S.J. (2004) Use of MDA (the "love drug") and methamphetamine in Toronto by unsuspecting users of ecstasy (MDMA). J Forensic Sci 49:1106-1112
40. Kenyon SL, Ramsey JD, Lee T, Johnston A., Holt D.W. (2005) Analysis for identification in amnesty bin samples from dance venues. Ther Drug Monit 27:793-798
41. Kolbrich EA, Goodwin RS, Gorelick D.A., Hayes RJ, Stein EA, Huestis M.A. (2008) Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. J Clin Psychopharmacol 28:432-440
42. Liechti ME, Gamma A, Vollenweider F.X. (2001) Gender differences in the subjective effects of MDMA. Psychopharmacology Berl 154:161-168
43. Lin DL, Liu HC, Yin H.L. (2007) Recent paramethoxymethamphet-amine (PMMA) deaths in Taiwan. J Anal Toxicol 31:109-113
44. Lin JC, Bangs N, Lee H., Kydd RR, Russell B.R. (2009) Determining the subjective and physiological effects of BZP on human females. Psychopharmacology Berl 207:439-446
45. Lin JC, Jan RK, Lee H, Jensen M.A., Kydd RR, Russell B.R. (2011) Determining the subjective and physiological effects of BZP combined with TFMPP in human males. Psychopharmacology Berl 214:761-768
46. Lora-Tamayo C., Tena T, Rodríguez A, Moreno D., Sancho JR, Enseñat P, Muela F. (2004) The designer drug situation in Ibiza. Forensic Sci Int 140:195-206
47. Marona-Lewicka D., Rhee GS, Sprague J.E., Nichols D.E. (1995) Psychostimulant-like effects of p-fluoroamphetamine in the rat. Eur J Pharmacol 287:105-113
48. Matok I, Gorodischer R, Koren G., Sheiner E, Wiznitzer A, Levy A. (2009) The safety of metoclopramide use in the first trimester of pregnancy. N Engl J Med 360:2528-2535
49. Maurer HH, Kraemer T, Springer D., Staack R.F. (2004) Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidino-phenone types: a synopsis. Ther Drug Monit 26:127-131
50. McElrath K, O'Neill C (2011) Experiences with mephedrone pre- and post-legislative controls: perceptions of safety and sources of supply. Int J Drug Policy 22:120-127
51. Morefield KM, Keane M, Felgate P., White JM, Irvine R.J. (2011) Pill content, dose and resulting plasma concentrations of 3,4- methylendioxymethamphetamine (MDMA) in recreational 'ecstasy' users. Addiction 106:1293-1300
52. Murphy PN, Wareing M, Fisk J. (2006) Users' perceptions of the risks and effects of taking ecstasy (MDMA): a questionnaire study. J Psychopharmacol 20:447-455
53. Nagai F, Nonaka R, Satoh Hisashi Kamimura K (2007) The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 559:132-137
54. Pálenícek T, Balíková M, Rohanová M, Novák T, Horácek J, Fujáková M, Höschl C (2011) Behavioral, hyperthermic and pharmacokinetic profile of para- methoxymethamphetamine (PMMA) in rats. Pharmacol Biochem Behav 98:130-139
55. Parrott AC, Buchanan T, Scholey A.B., Heffernan T., Ling J, Rodgers J. (2002) Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users. Hum Psychopharmacol 17:309-312
56. Parrott AC (2004) Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity. Psychopharmacology Berl 173:234-241
57. Parrott AC (2006) MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress. J Psychopharmacol 20:147-163
58. Parrott AC, Rodgers J, Buchanan T., Ling J, Heffernan T, Scholey A.B. (2006) Dancing hot on Ecstasy: physical activity and thermal comfort ratings are associated with the memory and other psychobiological problems reported by recreational MDMA users. Hum Psychopharmacol 21:285-298
59. Peroutka SJ, Newman H, Harris H. (1988) Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuro- psychopharmacology 1:273-277
60. Rohanova M, Balikova M. (2009) Studies on distribution and metabolism of para-methoxymethamphetamine (PMMA) in rats after subcutaneous administration. Toxicology 259:61-68
61. Schifano F, Corkery J, Deluca P., Oyefeso A, Ghodse A.H. (2006) Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures, related offences, prices, dosage levels and deaths in the UK (1994-2003). J Psychopharmacol 20:456-463
62. Schifano F, Albanese A, Fergus S., Stair JL, Deluca P, Corazza O, Davey Z., Corkery J, Siemann H, Scherbaum N, Farré M, Torrens M, Demetrovics Z, Ghodse AH, Psychonaut Web Mapping; ReDNet Research Groups (2011) Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues. Psychopharmacology Berl 214:593-602
63. Simonsen KW, Kaa E, Nielsen E., Rollmann D. (2003) Narcotics at street level in Denmark. A prospective investigation from 1995 to 2000. Forensic Sci Int 131:162-170
64. Staack RF (2007) Piperazine designer drugs of abuse. Lancet 369:1411-1413
65. Staack RF, Maurer H.H. (2003) Piperazine-derived designer drug 1-(3-chlorophenyl)piperazine (mCPP): GC-MS studies on its metabolism and its toxicological detection in rat urine including analytical differentiation from its precursor drugs trazodone and nefazodone. J Anal Toxicol 27:560-568
66. Sumnall HR, Cole JC, Jerome L. (2006) The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy. J Psychopharmacol 20:670-682
67. Tancer ME, Johanson C.E. (2001) The subjective effects of MDMA and mCPP in moderate MDMA users. Drug Alcohol Depend 65:97-101
68. Tancer M, Johanson C.E. (2003) Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with D-amphetamine and mCPP Drug Alcohol Depend 72:33-44
69. Tanner-Smith EE (2006) Pharmacological content of tablets sold as "ecstasy": results from an online testing service. Drug Alcohol Depend 83:247-254
70. Thomasius R, Petersen K, Buchert R., Andresen B, Zapletalova P, Wartberg L., Nebeling B, Schmoldt A (2003) Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology Berl 167:85-96
71. Thompson I, Williams G, Caldwell B., Aldington S, Dickson S, Lucas N., McDowall J, Weatherall M, Robinson G, Beasley R (2010) Randomised double-blind, placebo-controlled trial of the effects of the 'party pills' BZP/TFMPP alone and in combination with alcohol. J Psychopharmacol 24:1299-1308
72. UNODC (2010) United Nations Office on Drugs and Crime, World Drug Report 2010, http://www.unodc.org/documents/wdr/WDR-2010/World-Drug-Report-2010-lo-res. pdf
73. Verheyden SL, Hadfield J, Calin T., Curran H.V. (2002) Sub-acute effects of MDMA (+/-3,4-methylenedioxymethamphetamine, "ecstasy") on mood: evidence of gender differences. Psycho-pharmacology Berl 161:23-31
74. Vogels N, Brunt TM, Rigter S, van Dijk P, Vervaeke H, Niesink R.J. (2009) Content of ecstasy in the Netherlands: 1993-2008. Addiction 104:2057-2066
75. Wee S, Anderson KG, Baumann M.H., Rothman RB, Blough BE, Woolverton W.L. (2005) Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. J Pharmacol Exp Ther 313:848-854
76. Winstock AR, Mitcheson LR, Deluca P, Davey Z., Corazza O, Schifano F. (2011) Mephedrone, new kid for the chop? Addiction 106:154-161